Tenaya Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Tenaya Therapeutics's estimated annual revenue is currently $10.4M per year.
- Tenaya Therapeutics's estimated revenue per employee is $155,000
- Tenaya Therapeutics's total funding is $50M.
- Tenaya Therapeutics has 67 Employees.
- Tenaya Therapeutics grew their employee count by 31% last year.
- Tenaya Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Tenaya Therapeutics?
Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group. The Company was founded in 2016 by world-leading scientists from the Gladstone Institute's Cardiovascular Division and the University of Texas Southwestern Medical Center. Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.keywords:N/A
Number of Employees
Employee Growth %
Tenaya Therapeutics News
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tenaya Therapeutics a biopharmaceutical company focused on developing potentially ...
California, USA-based biopharma company Tenaya Therapeutics, which is focused on developing potentially curative treatments for heart ...
SOUTH SAN FRANCISCO, Calif., July 30, 2018 /PRNewswire/ -- Tenaya Therapeutics, a preclinical-stage biotechnology company focused on ...
Tenaya Therapeutics Executive Hires
|2017-11-02||Tim Hoey||Chief Scientific Officer||Article|
|2018-07-31||Faraz Ali||Chief Executive Officer||Article|
|2019-03-14||Whittemore Tingley||Chief Medical Officer||Article|